1. Home
  2. CBIO vs NL Comparison

CBIO vs NL Comparison

Compare CBIO & NL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • NL
  • Stock Information
  • Founded
  • CBIO 2003
  • NL 1891
  • Country
  • CBIO United States
  • NL United States
  • Employees
  • CBIO N/A
  • NL N/A
  • Industry
  • CBIO
  • NL Major Chemicals
  • Sector
  • CBIO
  • NL Industrials
  • Exchange
  • CBIO Nasdaq
  • NL Nasdaq
  • Market Cap
  • CBIO 308.0M
  • NL 320.5M
  • IPO Year
  • CBIO N/A
  • NL N/A
  • Fundamental
  • Price
  • CBIO $14.29
  • NL $6.52
  • Analyst Decision
  • CBIO Strong Buy
  • NL Sell
  • Analyst Count
  • CBIO 5
  • NL 1
  • Target Price
  • CBIO $25.60
  • NL $6.00
  • AVG Volume (30 Days)
  • CBIO 98.3K
  • NL 27.5K
  • Earning Date
  • CBIO 07-31-2025
  • NL 08-06-2025
  • Dividend Yield
  • CBIO N/A
  • NL 5.50%
  • EPS Growth
  • CBIO N/A
  • NL 141.37
  • EPS
  • CBIO N/A
  • NL 1.10
  • Revenue
  • CBIO N/A
  • NL $152,721,000.00
  • Revenue This Year
  • CBIO N/A
  • NL $15.75
  • Revenue Next Year
  • CBIO N/A
  • NL $2.44
  • P/E Ratio
  • CBIO N/A
  • NL $5.96
  • Revenue Growth
  • CBIO N/A
  • NL N/A
  • 52 Week Low
  • CBIO $10.83
  • NL $5.29
  • 52 Week High
  • CBIO $21.40
  • NL $9.42
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • NL 51.90
  • Support Level
  • CBIO $13.50
  • NL $6.30
  • Resistance Level
  • CBIO $16.00
  • NL $6.82
  • Average True Range (ATR)
  • CBIO 0.79
  • NL 0.33
  • MACD
  • CBIO 0.16
  • NL 0.04
  • Stochastic Oscillator
  • CBIO 39.68
  • NL 60.00

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About NL NL Industries Inc.

NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.

Share on Social Networks: